Immunic Inc (NASDAQ:IMUX) Chief Scientific Officer Hella Kohlhof speaks to Thomas Warner at the Proactive London after returning from MSMilan2023, the 9th Joint ECTRIMS-ACTRIMS meeting. She shares some of the main talking points from the event, noting keen interest in forms of multiple sclerosis (MS) not characterised by relapses and saying that for Immunic, the most important was the focus on biomarkers.
Shortly ahead of the conference Immunic had disclosed interim data from their phase two clinical study on progressive MS, revealing a significant decrease in neurofilament light chain compared to a placebo. Additionally, the company presented data from a phase two study in Relapsing Multiple Sclerosis (RMS), indicating promising results with only a 5.8% confirmed disability worsening rate.
She concludes by saying that the company's MS program is going "great" overall, and expresses optimism about the direction of the company's research, emphasising the connection between their preclinical work and promising clinical trials outcomes.
Proactive United States
View source version on newsdirect.com: https://newsdirect.com/news/immunic-cso-hails-great-progress-with-ms-program-576781503